Atreca has raised $125m to step up research and development around the fresh approach to drug discovery that is continuing to attract attention. The company has received $91m through venture capital rounds in recent years, investors including GlaxoSmithKline and the Bill & Melinda Gates Foundation supporting its method of probing the B-cell responses to identify novel antibodies and the targets that engage with them. In a statement, Dr David Sinclair, chief executive of AstraZeneca, said: “Today’s announcement by Roche Pharmaceuticals underscores our commitment to developing new medicines for patients suffering from serious diseases. Existing backers Wellington Management and Cormorant Asset Management contributed, with several new investors also coming aboard.
Atreca has raised $125m to step up research and development around the fresh approach to drug discovery that is continuing to attract attention. The company has received $91m through venture capital rounds in recent years, investors including GlaxoSmithKline and the Bill & Melinda Gates Foundation supporting its method of probing the B-cell responses to identify novel antibodies and the targets that engage with them. The latest series C round was led by an anonymous "large US-based healthcare-focused fund" that has bankrolled Atreca's rise. Existing backers Wellington Management and Cormorant Asset Management contributed, with several new investors also coming aboard.